Amgen (AMGN) May weekly 277 straddle into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Amgen (AMGN) PT Raised to $307 at UBS
May 3, 2024 7:06 AM EDTUBS analyst Colin Bristow raised the price target on Amgen (NASDAQ: AMGN) to $307.00 (from $284.00) while maintaining a Neutral rating.
The analyst comments "The much anticipated MariTide interim completed (earlier than we expected) with mgmt providing positive qualitative commentary, as we had expected. At face... More
Amgen (AMGN) PT Lowered to $328 at RBC Capital
May 3, 2024 6:35 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Amgen (NASDAQ: AMGN) to $328.00 (from $332.00) while maintaining a Outperform rating.
The analyst comments "GLP-1/GIPR, MariTides stated success on the ph.II interim data look internally takes the cake on the call,... More
Goldman Sachs Comments on Amgen (AMGN)
May 3, 2024 5:53 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Conviction Buy rating and $350.00 price target on Amgen (NASDAQ: AMGN)
The analyst comments "AMGN reported 1Q earnings (in-line top- and bottom-line; details within), with shares trading up significantly post-market (+15%; adding ~$20bn in market cap) as management provided a positive high-level interim update from the ongoing Ph2 study for MariTide in obesity, noting: (1) a differentiated profile vs. currently available therapies (e.g., LLYs Zepbound and NVOs Wegovy), as well as those in clinical development, (2) plans to rapidly advance a broad... More
